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Understanding regulation of mitochondrial DNA (mtDNA) expression is of considerable interest given that
mitochondrial dysfunction is important in human pathology and aging. Similar to the situation in bacteria,
there is no compartmentalization between transcription and translation in mitochondria; hence, both pro-
cesses are likely to have a direct molecular crosstalk. Accumulating evidence suggests that there are impor-
tant mechanisms for regulation of mammalian mtDNA expression at the posttranscriptional level. Regulation
of mRNA maturation, mRNA stability, translational coordination, ribosomal biogenesis, and translation itself
all form the basis for controlling oxidative phosphorylation capacity. Consequently, a wide variety of inherited
human mitochondrial diseases are caused by mutations of nuclear genes regulating various aspects of mito-
chondrial translation. Furthermore, mutations of mtDNA, associated with human disease and aging, often
affect tRNA genes critical formitochondrial translation. Recent advances inmolecular understanding ofmito-
chondrial translation regulation will most likely provide novel avenues for modulating mitochondrial function
for treating human disease.Introduction
Expression of mitochondrial DNA (mtDNA) is essential for
biogenesis of the oxidative phosphorylation system (Larsson
et al., 1998) and has a complex regulation at various levels,
such as genome maintenance, transcription initiation, mRNA
stability, and translation (Falkenberg et al., 2007). Therefore, it
is not surprising that mutations of mtDNA are major causes of
human disease and are also heavily implicated in common
forms of age-associated disease and the aging process (Lars-
son, 2010). Human pathogenic mtDNA mutations were first
described more than 25 years ago (Holt et al., 1988; Wallace
et al., 1988), and it soon became apparent that many of them
affect tRNA genes and thereby impair mitochondrial translation
(Larsson and Clayton, 1995). Two mutations (m.1555A > G and
m.1494C > T) in the 12S rRNA gene of mtDNA predispose to
maternally inherited aminoglycoside-induced deafness (Prezant
et al., 1993; Vandebona et al., 2009; Zhao et al., 2004). This also
shows that side effects of commonly used antibiotics can orig-
inate in the mitochondrial translation system. During the last
decade, it has become increasingly clear that also nuclear
gene mutations can impair mitochondrial translation in order
to cause human mitochondrial disease (Boczonadi and Horvath,
2014; Ro¨tig, 2011). Furthermore, at least a subset of the many
different types of mtDNA mutations found in aging impair mito-
chondrial translation, and these mutations undergo clonal
expansion in order to create a mosaic pattern of respiratory
chain deficiency in many different aging mammalian tissues
(Larsson, 2010).
In this review, we will describe the principles for transmission,
maintenance, and expression of mtDNA with special emphasis
on mitochondrial translation. We will summarize the current
knowledge of the regulation of mitochondrial translation,226 Cell Metabolism 20, August 5, 2014 ª2014 Elsevier Inc.including novel insights into the biogenesis, structure, and func-
tion of the mitoribosome.
Transmission of mtDNA
It is estimated that the human mtDNA mutation rate is at least an
order of magnitude higher than the corresponding nuclear rate
(Pakendorf and Stoneking, 2005). The transmission of mamma-
lian mtDNA is asexual, given that it is strictly maternally inherited
(Kaneda et al., 1995) and does not undergo germline recombina-
tion (Hagstro¨m et al., 2014). It has been predicted that any
genome with these features would undergo what is known as
the Muller’s ratchet effect, which is the accumulation of delete-
rious mutations over time that thereby causes a mutational melt-
down (Muller, 1964). Mammals have several poorly understood
mechanisms that counteract the Muller’s ratchet effect by
decreasing the inheritance of mtDNA mutations between gener-
ations: (1) the bottleneck phenomenon is a mechanism that en-
sures that only a subset of the molecules in the mother’s mtDNA
pool is transmitted to the offspring, which may lead to an mtDNA
genotype shift in just a few generations (Hauswirth and Laipis,
1982), (2) there is a purifying selectionmechanism in the germline
that selectively removes the mtDNA mutations that cause amino
acid substitutions (Stewart et al., 2008a, 2008b), (3) there is a
mechanism in developing embryos that selects against fetuses
with high levels of pathogenic tRNA mutations (Freyer et al.,
2012), and (4) high mutation levels in the female germline
decrease fertility (Ross et al., 2013). Accumulation ofmtDNAmu-
tations is heavily implicated in human aging (Larsson, 2010), and
recent experimental data suggest that low levels of maternally
transmitted mtDNA mutations act synergistically with somatic
mutagenesis to increase the total mtDNA mutation load and
thus accelerate mammalian aging (Ross et al., 2013).
Figure 1. The Gene Content of Mammalian mtDNA and Encoded mRNAs
The mammalian mtDNA contains only one longer noncoding region, denoted the displacement (D) loop region, which contains regulatory sequences needed for
mtDNA replication and transcription. The mtDNA encodes 2 rRNAs (red boxes), 22 tRNAs (green boxes), and 11 mRNAs with 13 open reading frames (ORFs, blue
boxes). ThemRNAscontainnoor very short50 noncodingsequences (yellowboxes) preceding thefirst translation initiationcodon (AUA,AUU,orAUG). Furthermore,
most mRNAs lack 30 noncoding sequences (yellow boxes) between the stop codon (AGA, AGG, UAA, and UAG) and the short poly A tail. Two of the mRNAs (ND4/
ND4L and ATP6/ATP8) are bicistronic, and each contains two partly overlapping ORFs. The structure of the human mRNAs are shown in the right panel.
Cell Metabolism
ReviewMaintenance and Transcription of mtDNA
The cellular mtDNA copy number varies by several orders of
magnitude between tissues and is 1 3 105 in human oocytes
(Chen et al., 1995) and 3 3 103 in human fibroblasts (Kukat
et al., 2011). Recent work with superresolution microscopy has
shown that mammalian mtDNA is packaged into compacted
nucleoid structures with a mean size of 100 nm (Brown et al.,
2011; Kukat et al., 2011). Most nucleoids seem to contain just
a single copy of mtDNA, and the main packaging factor is the
high-mobility group box domain protein called mitochondrial
transcription factor A (TFAM) (Kukat et al., 2011). TFAM binds
mtDNA cooperatively and can increase the flexibility of mtDNA
and bend it in order to facilitate compaction (Fisher et al.,
1992; Hallberg and Larsson, 2011; Ngo et al., 2011, 2014;
Rubio-Cosials et al., 2011; Farge et al., 2012). Although TFAM
is the main factor in the packaging of mtDNA, it is possible that
other proteins also make significant contributions to the struc-
ture of the nucleoid (Kukat and Larsson, 2013).
The two strands of mtDNA, which can be separated by
buoyant density ultracentrifugation, are, for historical reasons,
called the heavy (H) and light (L) strands (Figure 1) (Battey and
Clayton, 1978). Replication of mtDNA is often abortive and leads
to the formation of a triple-stranded structure called the
displacement (D) loop, which contains a prematurely terminated
nascent H strand. The D loop region contains the origin for initi-
ation of H (leading) strandmtDNA replication (OH), which requires
an RNA primer formed by transcription at the L strand promoter
(LSP). After mtDNA replication has been initiated, a poorly under-
stood mechanism operating at the end of the D loop will deter-
mine whether it will be abortive and lead to the formation of a
D loop structure or proceed and result in the replication of the
whole mtDNA molecule (Brown and Clayton, 2002). The replica-
tion of the lagging strand is initiated when leading-strand mtDNAreplication is two-thirds complete and the L strand replication
origin (OL) is activated (Clayton, 1982). Once it has been exposed
in its single-stranded form, OL forms a stem-loop structure to
which mitochondrial RNA polymerase (POLRMT) binds to pro-
duce the RNA primer necessary for initiation of lagging-strand
mtDNA replication (Wanrooij et al., 2008, 2012). There is
currently no scientific consensus about the mode of mtDNA
replication, and, in this regard, several other models have been
proposed (Lightowlers and Chrzanowska-Lightowlers, 2012).
The mammalian mtDNA contains a dedicated main promoter
for the transcription of each strand called the LSP and the H
strand promoter (HSP). The basal transcription initiation machin-
ery consists of three proteins: POLRMT, TFAM, and the mito-
chondrial transcription factor B2 (Falkenberg et al., 2002; Shi
et al., 2012). It is important to note that TFAM has dual roles
because it is required for both transcription initiation (Shi et al.,
2012) and the packaging of mtDNA into nucleoids (Bogenhagen
et al., 2008; Ekstrand et al., 2004). There has been a longstanding
hypothesis that the genes encoding rRNAs and mRNAs on the H
strand are transcribed from two distinct promoters called HSP1
and HSP2, respectively (Kruse et al., 1989). According to this
model, transcription initiated at HSP1 is terminated immediately
downstream of the rRNA genes as the mitochondrial transcrip-
tion termination factor 1 (MTERF1) binds its target sequence in
the tRNAL(UUR) gene (Figure 1) (Kruse et al., 1989; Martin et al.,
2005). However, a recent knockout of the mouse Mterf1 gene
has shown that the loss of MTERF1 does not affect rRNA gene
expression, whereas the amount of antisense RNAs increases
(Terzioglu et al., 2013). This result suggests that there is only
one transcription unit for expression of H strand genes that is
regulated by a single HSP (Terzioglu et al., 2013). Contrary to
previous assumptions, the main function of MTERF1 seems to
be to prevent transcription initiated at LSP from proceedingCell Metabolism 20, August 5, 2014 ª2014 Elsevier Inc. 227
Figure 2. Posttranscriptional Maturation of
mtDNA-Encoded RNAs
Each strand of mtDNA is transcribed as a long
polycistronic transcript that is subsequently pro-
cessed to release the individual mRNAs, tRNAs,
and rRNAs. The mitochondrial RNase P consists
of three subunits (MRPP1–MRPP3) and cleaves
the primary transcript at the 50 end of tRNAs.
MRPP1 and MRPP2 are responsible for an N1
methylation of mitochondrial tRNAs. The tRNAs
are released by cleavage at their 30 ends by
RNase Z (ELAC2). Yellow dots indicate RNA
modifications.
Cell Metabolism
Reviewover the rRNA gene region in order to produce antisense tran-
scripts. It is possible that such antisense transcripts may be
disadvantageous, given that they may prevent proper folding
of the 12S and 16S rRNAs. In addition, antisense transcription
has been shown to interfere with LSP activity, possibly by tran-
scriptional collision preventing reinitiation of transcription (Ter-
zioglu et al., 2013).
Mitochondrial RNA Processing
Transcription by POLRMT yields two long transcripts, one origi-
nating from LSP and the other from HSP. These two long tran-
scripts are processed by the mitochondrial RNA-processing
machinery in order to release the individual tRNAs, rRNAs, and
mRNAs (Figure 2). The processing is initiated on the tRNA se-
quences in order to release, according to the generally accepted
tRNA punctuation model, the mRNAs and rRNAs that they inter-
sperse (Figures 1 and 2) (Ojala et al., 1981). However, not all
mRNAs are flanked by tRNA genes, as exemplified by ATP6-
COIII and ND5-Cyt b (Figure 1). The pentatricopeptide repeat
domain 2 (PTCD2) protein has been reported to be involved in
processing of ND5-Cyt b (Xu et al., 2008), but it is otherwise
unclear how mRNAs not flanked by tRNAs are processed.
Evidence is accumulating to indicate that the early tran-
script processing takes place cotranscriptionally in small distinct
speckles tentatively named mitochondrial RNA granules (MRGs)
(Antonicka et al., 2013; Jourdain et al., 2013; Lee et al., 2013).
The mitochondrial 50-processing machinery in the form of the
mitochondrial protein-only version of RNase P, consisting of
three subunits (MRPP1–MRPP3), is found in these granules. In
contrast, RNase Z, which constitutes the 30-processing machin-
ery of tRNAs, is not present in the MRGs (Jourdain et al., 2013).
This fact, in combination with the primary structure of the inter-228 Cell Metabolism 20, August 5, 2014 ª2014 Elsevier Inc.mediates that are formed upon knock-
down of the 50- and 30-tRNA-processing
machinery and the known inhibition of
RNase Z by long 50 leaders (Rossmanith
et al., 1995; Levinger et al., 2001; Nashi-
moto et al., 1999), argues that the 50 end
of the tRNAs are processed first and the
30 ends in a subsequent step (Figure 2).
RNase Z in mammalian mitochondria
consists of ELAC2 (Brzezniak et al.,
2011; Rossmanith, 2011) possibly in
complex with PTCD1 (Sanchez et al.,
2011). According to this model, the pri-
mary transcripts undergo an initial andpartly cotranscriptional processing in the MRGs followed by a
second round of processing outside the MRGs.
Two of the three subunits of mitochondrial RNase P (MRPP1,
and MRPP2) form a strong complex, whereas MRPP3 binds the
complex weakly and only under low-salt conditions in vitro (Holz-
mann et al., 2008). MRPP1 shows strong sequence homology to
a family of tRNA N1-methyltransferases that methylate on posi-
tion 9 in tRNAs, and this modification is critical for obtaining a
cloverleaf fold of mitochondrial tRNAK (Helm et al., 1998,
1999). Elegant single-molecule FRET experiments have shown
an equilibrium between an extended nonphysiological confor-
mation and a cloverleaf conformation of mitochondrial tRNAK
(Voigts-Hoffmann et al., 2007). The reason for the extended non-
physiological conformation is the possibility of a Watson-Crick
base pairing between A9 and U64 in mitochondrial tRNAK. How-
ever, methylation of A9 renders the A9-U64 Watson-Crick base
pairing sterically impossible, hence shifting the balance to a
cloverleaf conformation. Interestingly, it was recently shown
that the RNase P subcomplex of MRPP1-MRPP2was necessary
and sufficient for N1-methylation of both A andG (m1R9) of mito-
chondrial tRNAs (Vilardo et al., 2012). The methylation was
shown to be rate limiting, so one can envision that the pre-
tRNA structure of the primary transcript is bound by the
MRPP1-MRPP2 subcomplex and that MRPP3 then comes in
and trims the 50 end while the tRNA is being methylated on R9.
Given that the m1R9 methylation is likely to be crucial for clover-
leaf formation for a majority of mitochondrial tRNAs, it is most
likely important that the tRNA gets this modification before it is
released by the tRNA 50- and 30-processing machinery.
The CCA in the acceptor stem of tRNAs is not encoded by
mtDNA. Instead, it is added by the mitochondrial CCA-adding
enzyme TRNT1 (Nagaike et al., 2001). Once the CCA sequence
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strate for RNase Z because the CCA addition is an antidetermi-
nant for RNase Z (Mohan et al., 1999). This arrangement makes
unproductive cycling between TRNT1 and RNase Z impossible.
Mitochondrial mRNA Stability and Polyadenylation
The release of the 11 mtDNA-encoded mRNAs (Figure 1) occurs
by RNA-processing events, as discussed above. Remarkably,
the ND6 mRNA seems to be immediately competent for transla-
tion once liberated from the primary transcript and does not need
any additional maturation steps. The ND6 mRNA contains no 50
untranslated region (UTR) and has a relatively short 30 UTR that is
not polyadenylated in humans (Temperley et al., 2010a) andmice
(Ruzzenente et al., 2012). Also, the other 10 mRNAs have no or
strikingly short 50 UTRs and often completely lack a 30 UTR
(Figure 1) (Montoya et al., 1981; Temperley et al., 2010a)
Two mRNAs, ND4L/ND4 and ATP8/ATP6, are bicistronic, and
each of them contain two open reading frames (ORFs) that are
partly overlapping (Figure 1). It is possible that both ORFs are
translated by a single interaction event between the mRNA and
the ribosome; e.g., by first translating the 50 ORF and then back-
tracking and repositioning to translate the 30 ORF. Alternatively,
the mRNA may be released after translation of the 50 ORF and
a second interaction event facilitated by an undefined internal
ribosome entry site of the mRNA may allow translation of the 30
ORF. In this latter case, the mRNA would contain a long 50 or
30 UTR, depending on which ORF is subject to translation.
A 7-methylguanosine cap at the 50 end of nucleus-encoded
mRNAs is essential for translation in unicellular eukaryotes and
metazoans (Cowling, 2010), but this modification is lacking in
themtDNA-encodedmRNAs (Grohmann et al., 1978). All mRNAs
except ND6 contain short polyadenylation tails of 45–50 nt in
length (Figure 1) (Ojala et al., 1981). A mitochondrial polyA poly-
merase (mtPAP) is required for polyadenylation of the mitochon-
drial mRNAs (Nagaike et al., 2005; Tomecki et al., 2004).
Decreased polyadenylation affects the stability of a subset of
mRNAs and leads to impaired mitochondrial translation and
mitochondrial dysfunction (Nagaike et al., 2005; Tomecki et al.,
2004). The importance of mtPAP is further underscored by the
finding that an autosomal recessive mutation in its gene leads
to defective mRNA polyadenylation and clinical manifestations
such as spastic ataxia and optic atrophy (Crosby et al., 2010).
The 20 phosphodiesterase PDE12 has been reported to remove
polyA tails from mitochondrial mRNAs (Rorbach et al., 2011).
The leucine-rich pentatricopeptide repeat (PPR)-containing
(LRPPRC) protein belongs to the large family of PPR proteins
that bind RNA and members of which are predominantly found
in organelles (Small and Peeters, 2000; Barkan et al., 2012).
LRPPRC is mainly present in the mitochondrial matrix (Sterky
et al., 2010), where it controls mRNA stability (Sasarman et al.,
2010). Mice with knockout of Lrpprc and fruit flies with
decreased expression of the fly ortholog of LRPPRC, called
Bicoid stability factor (dmLRPPRC), have drastically reduced
steady-state levels of mRNAs and drastically decreased polya-
denylation of mRNAs and transcript processing defects (Bratic
et al., 2011; Harmel et al., 2013; Ruzzenente et al., 2012). Inter-
estingly, LRPPRC seems to stabilize a pool of translationally
inactive transcripts, and mitochondrial translation becomes
chaotic and uncoordinated in the absence of LRPPRC in mam-mals and flies (Bratic et al., 2011; Ruzzenente et al., 2012).
Consistent with the genetic studies, in vitro biochemistry has
shown that LRPPRC suppresses RNA degradation by blocking
the action of polynucleotide phosphorylase (PNPase) and pro-
motes polyadenylation by stimulating the activity of mtPAP
(Chujo et al., 2012). LRPPRC and the stem-loop-interacting
RNA binding protein (SLIRP) form a stable complex (Ruzzenente
et al., 2012; Sasarman et al., 2010). SLIRP becomes unstable
and is degraded in the absence of LRPPRC, and both proteins
seem to act synergistically in order to promote mRNA stability
(Ruzzenente et al., 2012). Mutations in the gene encoding the
LRPPRC protein cause the French Canadian type of Leigh syn-
drome (LSFC), a severe form of infantile neurodegeneration
associated with deficient oxidative phosphorylation (Mootha
et al., 2003; Mourier et al., 2014; Xu et al., 2004). The pathophys-
iology of the mitochondrial dysfunction in LSFC patients is not
fully understood but most likely involves defective regulation of
mRNA stability, mRNA maturation, and translation.
Mitochondrial tRNA Modification
All mammalian mitochondrial tRNAs have rather high adenine
and uracil content, and some tRNAs, such as tRNAS(AGY), have
noncanonical secondary structures. Others, such as tRNAD
and tRNAF, lack the conventional stabilizing intramolecular inter-
actions between the D-T loops. This inherent poor stability
makes tRNAs in mammalian mitochondria more sensitive to pro-
cessing and modification defects than, for example, bacterial
tRNAs. There are more than 200 disease-related mutations of
tRNA genes in mtDNA, and more than half of them can be re-
garded as definitely pathogenic (Yarham et al., 2010). Themajor-
ity of these mutations are in positions subcritical to core tRNA
function, and their pathogenicity is the result of hindrance of
the proper recognition by the mitochondrial tRNA-modification
machinery.
Modifications of tRNAs can be divided into two subgroups:
those that are important for the overall structure and those that
are important for decoding (i.e., codon-anticodon recognition).
One of the important modifications for the overall structure of
the mitochondrial tRNAs, m1A9, or m1G9, is introduced already
when the 50 processing of the tRNA occurs, as discussed above.
However, the relative order of the ensuing modifications is
currently unknown. To this end, the interdependence of different
modifications should be studied with cell lines or mouse models
with knockdowns or knockouts of tRNA-modification enzymes.
In the following section, we shall focus on modifications that
are related to human disease and that are located in the anti-
codon stem loop.
In several mitochondrial tRNAs, a wobble-position uridine is
modified by a rather large adduct on the C5 atom of the uracil
base. Themodification, tm5U (Figure 3), is needed for the correct
codon-anticodon pairing for several mitochondrial tRNAs (Kur-
ata et al., 2003). Specifically, the modification has been shown
to stabilize U-G wobble pairing, at least when bound to a bacte-
rial ribosome (Kurata et al., 2008). Taurine is themajor part of this
adduct and is connected to the uracil-base C5 through a meth-
ylene moiety (Figure 3). The taurine moiety is dietary (Suzuki
et al., 2002), whereas the carbon source of the methylene moiety
is unknown. The modification is unique for animal mitochondria,
although there are similar adducts (cmnm5) in bacteria and yeastCell Metabolism 20, August 5, 2014 ª2014 Elsevier Inc. 229
Figure 3. RNA Modifications Present in Mitochondria
Nucleobases with modifications that are found in mitochondrial RNA and
discussed in the main text. The base modifications are highlighted with a
lighter background. The cmnm5U modification is only present in bacteria and
yeast mitochondria but is shown for comparison to the mammalian mito-
chondrial taurine-based modifications.
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modification of animal mitochondria tRNA is unknown, the
mechanism of cmnm5 modification (Figure 3) in bacteria and
yeast mitochondria is well studied. In the bacterial case, a com-
plex of two proteins (MnmE and MnmG) is sufficient and neces-
sary to use a glycine and tetrahydrofolate derivative to make
cmnm5. In yeast, it is clear that the presence of cmnm5 in mito-
chondrial tRNA requires MSS1 and MTO1 (Umeda et al., 2005),
although the biochemical activity of this protein complex remains
to be reconstituted in vitro. Homologs to MSS1 and MTO1 are
also present in humans (hGTPBP3 and hMTO1), but it is unclear
whether a suitable tetrahydrofolate derivative is available as a
cosubstrate in human mitochondria. Therefore, it is uncertain
how the first step of the modification, which gives rises to the
methylene moiety, is carried out. Defects in taurine modification
are implicated in mitochondrial encephalomyopathy, lactic
acidosis and stroke-like episodes syndrome (MELAS) as one
causative mutation in tRNAL(UUR) prevents recognition by the
tRNA-taurine modification system (Kirino et al., 2005; Yasukawa
et al., 2000). Out of the pool of taurine-modified mitochondrial
tRNAs, three (tRNAE, tRNAK, and tRNAQ) are further modified
with a thiolation of the 2 position on the wobble tm5U to make
tm5s2U (Figure 3). A similar thiolation on a canonical U base is
catalyzed by thiouridylase MnmA in bacteria (Ikeuchi et al.,
2006). MTU1 is the mitochondrial homolog of MnmA and knock-
down of MTU1 diminished detectable s2U and reduced oxida-
tive phosphorylation (Umeda et al., 2005). Point mutations in
MTU1 have been identified in patients with acute infantile liver
failure. The identified point mutations rendered either amino
acid changes in MTU1 or exon skipping and samples from the
patients showed loss of 2-thiolation in the mitochondrial tRNAE,
tRNAK, and tRNAQ (Zeharia et al., 2009).
Another enzyme involved in modifications in the anticodon
stem loop is pseudouridine synthase 1 (PUS1), which targets a
large range of cellular RNAs, both cytosolic and mitochondrial.
Specifically, U27 and U28 in several mitochondrial tRNAs
(tRNAK, tRNAM, tRNAL, tRNAI, and tRNAD) are pseudouridylated
by PUS1 at either one or both positions. These pseudouridine
modifications can potentially stabilize and preorder the anti-
codon stem loop in a confirmation amenable for the correct func-
tion on the ribosome (Agris, 2008). The structural-functional
aspects of the active site of pseudouridine synthases are
conserved in all classes of this large enzyme family (Ericsson
et al., 2004) and characterized by a conserved aspartate residue.230 Cell Metabolism 20, August 5, 2014 ª2014 Elsevier Inc.Different point mutations that are close in sequence or space to
the active site in PUS1 have been found in mitochondrial myop-
athy lactic acidosis and sideroblastic anemia patients (Fernan-
dez-Vizarra et al., 2007; Patton et al., 2005).
In the cytosol of eukaryotes, there are two main species of
tRNAM that are dedicated to either translation initiation or elon-
gation. However, the mitochondrial genome only encodes one
species of tRNAM. Intriguingly, this single species of tRNAM de-
codes not only AUG but also the canonical isoleucine codon
AUA in initiation and elongation. Furthermore, mitochondrial
tRNAM also decodes AUU and AUC, but only if they are the initi-
ating codons. Otherwise, they are decoded as isoleucine as in
the canonical code (Fearnley andWalker, 1987). Specifically, the
genes of ND1, ND2, ND3, and ND5 in humanmitochondria utilize
non-AUG start codons (Figure 1). To enable the proper codon-
anticodon recognition of these noncanonicalmethionine codons,
a formylation of the wobble C34 has been suggested and, in the
case of AUA, shown to be needed (Bilbille et al., 2011; Moriya
et al., 1994). The source of the formyl group and the responsible
enzyme(s) for this critical modification remain unclear.
Aminoacyltransferase Activity in Mitochondria
Just like in the eukaryotic cytosol and the bacterial cytosol,
tRNAs in mitochondria are specifically charged with amino
acids by aminoacyl-tRNA synthetases (aaRSs). However, a few
aspects of this charging process are idiosyncratic to mito-
chondria. There are 19 aaRSs in mitochondria, all encoded in
the nuclear genome, and, similar to the cytosolic case in
eukaryotes and bacteria, they can be divided into two classes
(classes I and II) on the basis of on their primary sequences.
There is no mitochondrial aaRS for tRNAQ. Instead, the aminoa-
cylation of tRNAQ follows an indirect pathway, and misaminoa-
cylation with E is followed by a transamidation to Q by the
heterotrimericmitochondrial amidotransferase hGatCAB (Nagao
et al., 2009).
In general, it is very important that tRNAs are properly recog-
nized by their cognate aaRSs, and recurring mischarging of
tRNAs severely reduces the overall translational fidelity. The
mitochondrial aaRSs are unusual in their relative lack of discrim-
inatory capacity and also, in some cases, disobeying the univer-
sal tRNA identity rules (Bonnefond et al., 2005; Giege´ et al.,
1998). It is likely that this is a consequence of the reduced
tRNA T and D loop sequences of mitochondrial tRNAs. As an
example, tRNAQ is easily misacylated by the aaRS for tRNAS
(Shimada et al., 2001). However, there appears to be a strong
discriminatory mechanism in place against wrongly charged
tRNAs in the binding step to elongation factor Tu (mtEFTu) (Na-
gao et al., 2007), although the molecular mechanism for this se-
lection remains elusive. In fact, a multitude of mitochondrial dis-
eases originates from mutations in mitochondrial aaRSs, but
defects in aminoacylation can also be caused by mutations in
the tRNA substrate, such as those observed for tRNAI and tRNAK
(Degoul et al., 1998; Sissler et al., 2004).
As discussed above, mitochondria have only a single gene
that encodes tRNAM, and a nucleus-encoded mitochondrial
methionyl-tRNA formyltransferase (MTFMT) formylates a subset
of charged tRNAM for use in translation initiation, whereas the
nonformylated species is used for translation elongation (Tucker
et al., 2011). Recessive mutations inactivating the MTFMT gene
Table 1. Positions of Modified Nucleotides in rRNA Relative to the mtDNA Sequence
Human Mouse
Type of Modification 12S rRNA 16S rRNA mtDNA 12S rRNA 16S rRNA mtDNA
m4C 839 1,486 840 909
m5C 841 1,488 842 911
m62 936, 937 1,583, 1,584 937, 938 1,006, 1,007
Gm 1,145, 1,370 2,815, 3,040 1,160, 1,389 2,253, 2,482
Um 1,369 3,039 1,388 2,481
pseudouridine 1,397 3,067 1,416 2,509
The numbering of nucleotide positions in 12S and 16S rRNA are from the first nucleotide at the 50 end of the mature transcript. The nucleotide positions
of the human andmouse mtDNA sequences are according to NCBI NC_012920 and NC_005089, respectively. The m5U425modification of 12S rRNA
is not included in this table.
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syndrome in children (Tucker et al., 2011).
Mitoribosome Biogenesis
The mitoribosome biogenesis pathway can be divided into
several distinct steps: (1) synthesis of 12S and 16S rRNA by tran-
scription of mtDNA; (2) nuclear gene expression to produce the
mitoribosomal proteins of the small (MRPS) and large (MRPL)
subunits, including possible posttranslational modifications of
some of these proteins; (3) posttranscriptional modification of
the rRNAs by methylation, 20-O-ribose methylation, and pseu-
douridylation of specific residues (Table 1); (4) assembly of 16S
rRNAandMRPLproteins to form the largesubunit (LSU)of themi-
toribosome; (5) assemblyof 12S rRNAandMRPSproteins to form
the small subunit (SSU) of the mitoribosome; and (6) assembly of
the mature SSU and LSU to functional mitoribosomes. It should
be noted that several of these steps may partly coincide, given
that some MRPs most likely assemble with the rRNAs already
during the transcription process (Bogenhagen et al., 2014).
In nuclear and bacterial ribosome biogenesis, the initial rRNA
processing and somemodification steps are largely cotranscrip-
tional (Henras et al., 2008; Kaczanowska and Ryde´n-Aulin,
2007). The rRNA methyltransferases RNMTL1, MRM1, and
MRM2 were recently found in speckles that contained newly
transcribed mitochondrial RNA (Lee et al., 2013), supporting a
cotranscriptional role in rRNAmodification. Whether or not these
structures are the same as the MRGs containing MRPP1–
MRPP3 remains to be determined. In contrast, other rRNA mod-
ifications occur late in the biogenesis process and require the
presence of rRNA/MRP assembly intermediates that are specif-
ically recognized by rRNA-modification enzymes (Metodiev
et al., 2009, 2014).
Translatingmitoribosomes in yeast are reported to be tethered
to the inner mitochondrial membrane by MRP20, which is a
homolog to bacterial L23 and human MRPL23. In yeast,
MRP20 is necessary for the formation of a ribosomal subcom-
plex with other proteins to achieve proper mitoribosome assem-
bly and function (Kaur and Stuart, 2011). This suggests that the
LSU of the mitoribosome is assembled on the inner mitochon-
drial membrane (Figures 4 and 5).
Modifications of 16S rRNA and Biogenesis of the LSU
It was observed early that the large subunit of mammalian mito-
ribosomes is, in comparison to its bacterial and cytosolic coun-terparts, quite scarcely modified (Dubin, 1974). Three ribose
methylations (human 16S numbering Gm1145, Um1369, and
Gm1370) have been reported from experiments in hamster cells
(Baer and Dubin, 1981). In yeast, the enzymes responsible for
the corresponding two first methylations in the large mitoriboso-
mal rRNA (Gm2270 and Um2791) have been identified as MRM1
(Pet56p) and MRM2, respectively (Sirum-Connolly and Mason,
1993; Pintard et al., 2002). Methylation by MRM1 is crucial for
LSU (yeast 21S) stability, and the mitochondrial function is
compromised without this modification (Sirum-Connolly and
Mason, 1993). Likewise, MRM2 in yeast encodes an RNA-modi-
fying enzyme (Um2791), and LSU production is slightly reduced
upon MRM2 deletion (Pintard et al., 2002). Furthermore, the hu-
man homologs of MRM1 and MRM2 were recently shown to
localize to mitochondria (Lee et al., 2013), but whether they carry
out their presumed function (i.e., 20-O-ribose methylation of
G1145 and U1369, respectively) has not yet been verified. How-
ever, the enzyme responsible for the third observed 20-O-ribose
methylation of 16S rRNA Gm1370 was recently identified by Lee
et al. (2013) as RNMTL1.
Pseudouridinylation was not observed in the initial studies of
the large mitochondrial rRNA in hamster cells (Dubin and Taylor,
1978), although it could later be observed at U1397 inmouse and
human large mitochondrial rRNA with more sensitive methods
(Ofengand and Bakin, 1997). The enzyme responsible for the
corresponding modification in yeast mitochondria (Pus5) has a
range of human homologs, and it is currently unclear which, if
any, of these perform the modification (Ansmant et al., 2000).
The MTERF3 protein is predicted to bind nucleic acids (Spa˚hr
et al., 2010), and studies of Mterf3 knockout mice have shown
that MTERF3 is essential for embryogenesis and that its loss
leads to a dramatic upregulation of mitochondrial transcription
accompanied by severe respiratory chain deficiency (Park
et al., 2007). In a subsequent study, it was found that knockout
and downregulation of dmMTERF3 in fruit flies not only activates
mitochondrial transcription but also leads to impaired assembly
of the LSU of themitoribosome (Wredenberg et al., 2013). Similar
to the findings in flies, the biogenesis of the LSU and mitochon-
drial translation are severely impaired in Mterf3 knockout mice
(Wredenberg et al., 2013). RNA immunoprecipitation experi-
ments have shown that both MTERF3 and dmMTERF3 specif-
ically interact with 16S rRNA in mice and flies, respectively
(Wredenberg et al., 2013). Whether MTERF3 interacts with a
modifying enzyme to promote some specific type of rRNACell Metabolism 20, August 5, 2014 ª2014 Elsevier Inc. 231
Figure 4. Structure of the Large Subunit of
the Mammalian Mitoribosome
Rendered from the 4.9 A˚ EM structure of the large
subunit of the porcine mitoribosome (Greber et al.,
2014). rRNA is colored in light beige, and ribo-
somal proteins that are not specifically denoted
are colored in green. The RNA found to be bound
to MRPL18 in the structure is denoted ‘‘RNA X.’’
Cell Metabolism
Reviewmodification or has another function in the biogenesis of the LSU
is currently unknown.
The C7orf30 protein interacts with the LSU of the mitoribo-
some (Wanschers et al., 2012) and promotes its biogenesis (Ror-
bach et al., 2012). The C7orf30 protein has been reported to
interact with MRPL14, and downregulation of either of these
two proteins leads to the formation of an LSU lacking several
MRPLs that cannot be properly assembled into a monosome,
thereby resulting in severely impaired mitochondrial translation
(Fung et al., 2013).
Modifications of 12S rRNA and Biogenesis of the SSU
Five modifications have been identified in 13S rRNA of the SSU
of the hamster mitoribosome (Baer and Dubin, 1981), and these
are most likely conserved in all mammals. These modifications
were mapped to the mouse mitochondrial ribosome sequences
(Van Etten et al., 1980) and included two adenine dimethylations
(m62A
937 and m62A
938), one uracil methylation (m5U425), and two
cytosine methylations (m4C840 and m5C841 or m5C842) (Baer and
Dubin, 1981).
The presence of two dimethylated adenines in a stem-loop
structure at the 30 end of the rRNA of the SSU is highly conserved
in all domains of life (Shutt and Gray, 2006). In Escherichia coli,
the lack of the enzyme responsible for this modification, KsgA,
leads to resistance to the aminoglycoside kasugamycin and
growth retardation (Helser et al., 1971; Poldermans et al.,
1980). Mouse knockout studies show that loss of the Tfb1m
gene leads to embryonic lethality and complete absence of
m62A
937and m62A
938 of the 12S rRNA in mouse mitochondria
(Metodiev et al., 2009). Without these modifications, the levels
of the assembled SSU of the mitoribosome are drastically
reduced and mitochondrial translation is severely impaired
(Metodiev et al., 2009).
The mitochondrial cytosine methyltransferase NSUN4 be-
longs to the same family of m5C-methyltransferases as the bac-
terial rRNA m5C-methyltransferases RsmB, RsmF, and YccW
(Ca´mara et al., 2011). In contrast to the bacterial homologs,
NSUN4 lacks RNA binding domain extensions and instead forms
a stable complex withMTERF4 that targets the NSUN4/MTERF4
complex to the LSU of the mitoribosome (Ca´mara et al., 2011;
Spa˚hr et al., 2012; Yakubovskaya et al., 2012). Knockout of
either MTERF4 (Ca´mara et al., 2011) or NSUN4 (Metodiev232 Cell Metabolism 20, August 5, 2014 ª2014 Elsevier Inc.et al., 2014) is embryonically lethal and
appears to affect a late step in ribosomal
biogenesis, given that both the SSU and
LSU remain stable but do not interact to
form a functional monosome. Recent
sequencing of cDNA generated from
bisulfite-treated mouse mitochondrial
rRNA identified two cytosine methyla-tions (m4C840 and m5C842) in 12S rRNA (Metodiev et al., 2014)
corresponding to the modification sites previously identified in
hamstermitochondria (Baer and Dubin, 1981). Them4C840modi-
fication in mice has an E. coli homolog (m4C1402) that has been
proposed to regulate translational precision through functional
and conformational control of the ribosomal P site (Kimura and
Suzuki, 2010). In Nsun4 knockout mice, the m5C842 modification
of 12S rRNA is absent, whereas the m4C840 modification is pre-
served (Metodiev et al., 2014). Remarkably, the knockout of
MTERF4 does not affect the m5C842 modification, despite the
fact that NSUN4 and MTERF4 form a very stable heterodimeric
complex (Spa˚hr et al., 2012; Yakubovskaya et al., 2012). This
has led to a model in which a free fraction of NSUN4 is proposed
to be responsible for the creation of the m5C842 modification of
the 12S rRNA, whereas the NSUN4/MTERF4 complex has an
essential role in the final assembly step of the monosome by
binding the LSU to interact with the SSU (Metodiev et al.,
2014). It is possible that the m5C842 modification of the 12S
rRNA provides a quality control mark for ensuring that only fully
mature SSUs can interact with the LSU in the final assembly step
of the monosome (Metodiev et al., 2014). It is important to note
that the adenine dimethylations (m62A
937and m62A
938) of 12S
rRNA are established independently of NSUN4 (Metodiev
et al., 2014), which indicates that they may occur at an earlier
stage of the biogenesis of the SSU. Furthermore, the protein
encoded by C4orf14 has been reported to be necessary for
SSU biogenesis, although the molecular mechanisms are not
understood (He et al., 2012).
The Mammalian Mitoribosome
Mitoribosomes were found in mitochondrial isolates as early as
the mid-1950s, but, because of problems with proper mito-
chondrial isolation, their more detailed characterization required
another 10 years of methods development (O’Brien and Kalf,
1967).
The complete mammalian mitoribosome (55S) is made up of
the SSU (28S) and the LSU (39S). The SSU contains the 12S
rRNA and more than 29 proteins, 15 of which do not have any
obvious bacterial counterparts, whereas the LSU contains the
16S rRNA and 50 proteins, 20 of which have no obvious bacterial
counterparts (Sharma et al., 2003). This means that the mamma-
lian mitochondrial ribosome contains a mass ratio of RNA to
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eukaryotic cytosolic ribosomes is about 2:1 (Agrawal and
Sharma, 2012). The mitoribosome has a proteobacterial origin,
and, during evolution, certain rRNA segments have been lost,
whereas the share of protein has increased, and, as discussed
below, ribosomal proteins have replaced evolutionarily lost
rRNA segments in some regions.
About half of the MRPs do not have any bacterial homolog
identifiable by sequence alone, although it is probable that struc-
tural-functional aspects have been conserved in the absence of
sequence homology. Nevertheless, it is clear that there are some
unique proteins in the mitoribosome that have been acquired
over the evolutionary period as a consequence of rRNA compo-
nent loss. All mammalian MRPs are nuclear encoded and most
contain a mitochondrial localization sequence on the N terminus
(O’Brien, 2002).
Structure Description
The structure of the whole bovine mitoribosome has been deter-
mined by the Sharma et al. (2003) group with the use of cryo-
electron microscopy at relatively low (13.5A˚) resolution, and,
for a long time, this was the only available structural information
on mammalian mitoribosomes. However, very recently, the
Sharma et al. (2003) work was complemented by the 4.9 A˚ reso-
lution EM structure of the LSU of the pig mitoribosome by the
work of Greber et al. (2014) (Figure 4). A pertinent feature of
the EM structures is that the rRNA is almost completely covered
with protein. This is in stark contrast to the structures of the bac-
terial and the eukaryotic cytosolic ribosome, in which the protein
is found in only small patches on the rRNA. Another difference
from the bacterial and the eukaryotic cytosolic ribosomes is
that there is considerable space between the MRPs on the mito-
chondrial ribosome with several passages available for bulk
matrix solvent. This is one explanation for the fact that the sedi-
mentation rate is lower for the mitoribosome (55S) than E. coli
(70S), although the mass of the mitochondrial ribosome is
considerably larger at 2.7 MDa in comparison to 2.3 MDa for
the E. coli ribosome.
The LSU and SSU are connected by 15 intersubunit bridges,
of which only six are conserved in the bacterial ribosomes,
whereas the rest differ in their chemical or spatial arrangement
(Sharma et al., 2003; Kaushal et al., 2014). The mitoribosome
subunits are mainly joined by protein-protein bridges in contrast
to the bacterial counterpart, wherein most interconnection is by
RNA-RNA bridging. Furthermore, the mRNAs that enter the SSU
do so through an mRNA entrance lined with conserved mito-
chondrion-specific proteins (Kaushal et al., 2014). In fact, in
mammals, it is unknown how the more or less leaderless
mRNAs are recognized and transported to this gate. It has
been shown that the addition of just a few nucleotides 50 to
the translation start practically abolishes the translation of mito-
chondrial mRNAs that are normally devoid of a 50 UTR (Figure 1)
(Christian and Spremulli, 2010). This is in stark contrast to the
mRNA requirements of both bacterial and eukaryotic cytosolic
ribosomes, and it points to fundamental differences in mito-
chondrial translation initiation in comparison with translation
initiation in these systems.
All of the translation products from the mammalian mitoribo-
some are membrane proteins, and hence there are uniqueopportunities for adaptation and specialization of the mamma-
lian mitoribosome for the task of translating membrane proteins.
Indeed, it appears that the mitoribosome is normally bound to
the inner membrane, removing the need for cycling between
free and membrane-bound states, which occurs with the bacte-
rial and eukaryotic cytosolic ribosomes (Liu and Spremulli, 2000).
Furthermore, evidence is accumulating in favor of the claim that
the polypeptides are inserted cotranslationally into the inner
membrane (Gruschke and Ott, 2010).
From the EM structures of themitoribosome, it is apparent that
on top of the conventional polypeptide exit site (PES), there is
another channel (polypeptide accessible site [PAS]) some 25 A˚
from the PES where the newly formed peptide can also pass
out from the ribosome (Greber et al., 2014; Sharma et al.,
2003). Indeed, the human Oxa1L, which is important for insertion
of proteins into the mitochondrial inner membrane has been
reported to interact with the PAS but not the conventional PES
(Haque et al., 2010). It cannot be excluded that whether PAS
or PES is used depends on translation product.
From the higher resolution structure of the LSU from Greber
et al. (2014), it was apparent that the ring of proteins MRPL23,
MRPL47, MRPL22, MRPL24, and MRPL17 typically found
around the PES in homologous ribosomes has an outer layer
of proteins in the mammalian mitoribosome. Several of these
outer-layer proteins could be modeled into the electron density
(Figure 4), and their interactions could be validated through
crosslinking and mass spectrometry. Out of these novel outer-
layer proteins, perhaps the most interesting is MRPL45, which
shows strong homology to the membrane-associated yeast
TIM44 (Greber et al., 2014). Furthermore,MRPL45 is ideally posi-
tioned as to act as a membrane anchor of LSU on the inner
mitochondrial membrane in order to position the PES and
PAS toward the membrane insertion machinery. In addition,
MRPL45 forms a strong novel interaction with MRPL24, thereby
replacing the rRNA that has the L24-fixating role in the bacterial
ribosome. This is only one example of a situation in which the re-
ductively evolved 16S rRNA has left large voids on the surface of
the LSU and the functionality of the reduced rRNA has been
taken up by mitoribosomal proteins.
On the other side of the LSU, at the central proturberance (CP),
there are major differences in comparison to the bacterial ribo-
some. Although, this was clear already from the lower-resolution
structure of the whole mitoribosome by the Agrawal group, the
higher resolution in the newer LSU EM-structure permits
the modeling of several proteins into the electron density of the
CP. Here, MRPL52 takes on a prominent role, as it connects
the 39S body with the CP with a 50-residue-long helix (Figure 4).
This interaction replaces in part the 5S RNA in bacterial and
eukaryotic cytosolic ribosomes. Interestingly, a small piece of
RNA is found to bindMRPL18 in a similar fashion as the b domain
of 5S RNA bind L18 in the bacterial and eukaryotic cytosolic ho-
mologs (Figure 4). The identity of this piece of RNA is currently
unknown. The recent 3.2 A˚ resolution EM structure of the yeast
LSU also shows that the 5S rRNA is absent in the central protu-
berance of the LSU, but, in contrast to the porcine LSU, there is
no other shorter RNA present at this location (Amunts et al.,
2014). Instead, the central protuberance of the yeast LSU
consists entirely of mitochondria-specific ribosomal proteins
(Amunts et al., 2014).Cell Metabolism 20, August 5, 2014 ª2014 Elsevier Inc. 233
Figure 5. Biogenesis of the Mammalian Mitoribosomes and the Translation Cycle
The biogenesis of the mitoribosome requires that the 12S and 16S rRNAs are modified and assembled along with the ribosomal proteins. The large subunit of the
mitoribosome is believed to be anchored to the inner mitochondrial membrane, and the translation cycle requires several factors for initiation, elongation, and
termination. Themembrane anchoring of themitoribosome is believed to facilitate insertion of newly synthesized proteins into the inner mitochondrial membrane.
The recycling of the mitoribosome is not shown.
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Similar to bacterial and cytosolic ribosomes, mitochondrial
translation is a multistep process requiring several different
factors for initiation, elongation, termination, and recycling
(Figure 5). The mitochondrial translation process will only be
briefly summarized here, given that a detailed review of this pro-
cess has recently been published (Christian and Spremulli,
2012). Mitochondria contain two initiation factors (IFs), denoted
mtIF2 and mtIF3, whereas a homolog of the highly conserved
IF1 is lacking. However, there is a 37 amino acid insertion domain
in mtIF2 and this insertion was able to functionally replace IF1 in
E. coli (Gaur et al., 2008). Furthermore, the inserted peptide
sequence does bind on the eubacterial ribosome at a site where
normally the eubacterial IF1 would bind (Yassin et al., 2011). In
the first step, mtIF3 binds the SSU and dissociates the mono-
some to release the LSU. The SSUmtIF3 complex then interacts
with mtIF2, mRNA, and tRNA carrying formylated methionine
(tRNAfM). After the formation of this initiation complex, where
tRNAfM is bound to the start codon of the ORF of the mRNA,
mtIF2 hydrolyzes its bound GTP to GDP, and both initiation
factors are released when the LSU binds to start translation
(Figure 5).
The elongation phase ensues after the completion of the initi-
ation, when mtEFTu, which forms a ternary complex with GTP
and aminoacylated tRNA, enters the A site of the mitoribosome.
Base pairing of the tRNA anticodon with the codon contained in
the mRNA leads to conversion of GTP to GDP and release of
mtEFTu. The ribosome then catalyzes peptide bond formation
whereby the peptide chain of the tRNA present at the P site is
transferred to the newly entered aminoacylated tRNA of the A
site, thus leading to elongation of the peptide chain by one
amino acid. Next, binding of elongation factor G1 (mtEFG1) cat-
alyzes a translocation step that moves the tRNA with the
attached peptide chain from the A to the P site, simultaneously
moving the deacylated tRNA from the P to the E site. Then, the
cycle is repeated when mtEFTu again interacts with the ribo-
some in order to bring in the next aminoacylated tRNA.234 Cell Metabolism 20, August 5, 2014 ª2014 Elsevier Inc.At the end of the ORF, a stop codon is present, and no amino-
acylated tRNA can bind in order to continue peptide synthesis.
Instead, translation termination factors will interact with the
stop codon to release the nascent peptide chain from the ribo-
some (Chrzanowska-Lightowlers et al., 2011). In this context, it
should be noted that the genetic code in mammalian mitochon-
dria is somewhat different from the universal code, and there are
four different stop codons in mammalian mitochondria (UAA,
UAG, AGA, and AGG) (Anderson et al., 1981). Remarkably, seven
of the nine UAA stop codons are not fully encoded bymtDNA but
instead are only generated after the addition of one or two
adenine residues during polyadenylation (Anderson et al.,
1981). Mammalian mitochondria contain four translation termi-
nation factor homologs called mtRF1, mtRF1a, ICT1, and
C12orf65 (Antonicka et al., 2010; Richter et al., 2010; Soleiman-
pour-Lichaei et al., 2007), but the specific roles of each of these
factors is not fully understood at present. Three of the factors
mtRF1a, ICT1, and C12orf65 contain a classical GGQ sequence
motif in their active sites that catalyzes hydrolysis of the peptidyl-
tRNA bond. It has been reported that mtRF1a binds the nine UAA
and the two UAG codons in mitochondrial transcripts in order to
terminate translation (Soleimanpour-Lichaei et al., 2007). The
nonstandard stop codons AGA and AGG are present in the
COI and ND6 transcripts, respectively (Figure 1) and are pre-
ceded by uracil in humans. Translation pausing at these codons
followed by a 1 frame shift has been reported to create a UAG
stop codon in both of these transcripts to allow mtRF1a to bind
(Temperley et al., 2010b). However, recent homology modeling
has questioned this concept and instead argues that ICT1
directly binds the AGA and AGG stop codons (Lind et al.,
2013). After the completion of translation termination and release
of the nascent peptide chain, the ribosome needs to be recycled
through the disassembly of the two subunits and release of the
mRNA. The ribosomal recycling factors 1 (mtRRF1) and mtRRF2
(also known as elongation factor G2 or mtEFG2) are involved in
this GTP-dependent process inmammalianmitochondria (Chris-
tian and Spremulli, 2012).
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After the discovery of pathogenic single large deletions of human
mtDNA (Holt et al., 1988), it soon became evident that one or
more tRNA genes are always deleted (Mita et al., 1990). The
affected patients are always heteroplasmic (Mita et al., 1990),
and a fraction of >60%mutatedmtDNA is needed to impair mito-
chondrial translation (Hayashi et al., 1991). Children with high
levels of deleted mtDNA in multiple tissues typically develop a
multisystem disease with symptoms such as sideroblastic
anemia, pancreatic insufficiency, diabetes, and renal failure,
whereas adults often have a more limited tissue distribution of
deleted mtDNA and develop a predominantly neuromuscular
phenotype with symptoms such as progressive external oph-
thalmoplegia, myopathy, ataxia, and deafness (Larsson and
Clayton, 1995). Also, heteroplasmic point mutations in tRNA
genes are common causes of mitochondrial disease, and today
we know>200 suchmutations (Blakely et al., 2013). Although the
pathogenicity of half of thesemutations can be questioned, there
are still many mutations where overwhelming evidence shows
that they cause human disease (Blakely et al., 2013). The pheno-
types caused by different tRNA point mutations vary tremen-
dously, and specific point mutations can cause remarkably
different phenotypes in affected patients. One example is the
m.3243A < G mutation in tRNAL(UUR), which can cause MELAS
syndrome (Goto et al., 1990), progressive external ophthalmo-
plegia (Moraes et al., 1993), deafness, and diabetes (van den
Ouweland et al., 1992). Another example is them.8344A >Gmu-
tation in tRNAK (Shoffner et al., 1990), which, in some individuals,
can cause a severe type of mitochondrial neurodegeneration
called the myoclonus epilepsy with ragged red muscle fibers
syndrome. However, in other individuals of the same pedigree,
large lipomas of the neck are the only manifestation of the
m.8344A > G mutation (Holme et al., 1993; Larsson et al.,
1992). This phenotypic pleiotropism caused by pathogenic point
mutations of mtDNA-encoded tRNA genes is largely unex-
plained, and it has been speculated that the tissue distribution
ofmutant mtDNA and the nuclear genetic background of themu-
tation carrier are important determinants of the phenotype.
Given the extensive knowledge that has accumulated over
the last 20 years about the extreme variability in clinical mani-
festations caused by mtDNA mutations affecting tRNA genes,
it is perhaps not so surprising that mutations in nuclear genes
controlling mitochondrial translation have also been shown
to result in a tremendous variability of clinical symptoms. A
variety of mainly autosomal recessive mutations that impair
mitochondrial translation are known, and some examples of
mutated genes include those that encode mRNA stability and
polyadenylation factors (LRPPRC and mtPAP), tRNA-modifica-
tion enzymes (PUS1, MTU1, and MTO1), enzymes that amino-
acylate tRNAs (DARS2, RARS2, EARS2, MARS2, FARS2,
AARS2, YARS2, SARS2, HARS2, and LARS2), mitoribosomal
proteins (MRPS16, MRPS22, MRPS28, MRPL3, MRPL12, and
MRPL44), translation elongation and termination factors
(mtEFTu, mtEFG1, mtEFTs, and C12orf65), an enzyme for for-
mylation of methionine (MTFMT), and translational activators
of specific transcripts (TACO1) (Boczonadi and Horvath,
2014; Ro¨tig, 2011). The resulting diseases are often lethal
with a neonatal or infantile onset, and several recent reviewsprovide a detailed discussion about the severe clinical manifes-
tations (Boczonadi and Horvath, 2014; Ro¨tig, 2011). In several
instances, there is a relatively strong correlation between the
mutated gene and the resulting clinical phenotypes, including
neuropathological findings, as exemplified mutations in the
different genes encoding the enzymes that aminoacylate tRNAs
(Ro¨tig, 2011).
So why does impaired mitochondrial translation lead to such a
variability of clinical manifestations? In some instances, this is
due to poorly understood specific molecular events initiated by
the mutated gene. In other cases, genetic modification of the re-
sulting phenotype is likely to be an important determinant. It
should be noted that genetic modification of the phenotype is
also quite common in other types of genetic disease and even
an archetypal inherited disease, such as sickle cell anemia,
caused by a homozygous mutation that exchanges a single
amino acid in hemoglobin, show a substantial variation in the
severity of symptoms between different patients (Lettre, 2012).
The complexity of the mitochondrial translation machinery
means that a mutated, dysfunctional component will have direct
and indirect molecular interactions with a large number of other
components. All of these interactions can be subject to epistasis
and can thereby influence the overall impact on mitochondrial
protein synthesis. Furthermore, tissue-specific differences in
the abundance of different components of the mitochondrial
translation machinery and tissue-specific differences in the
dependence on oxidative phosphorylation will also have major
impact on the overall phenotype.Concluding Remarks
It is becoming increasingly clear that translational regulation is a
major determinant of mammalian mtDNA expression, which is
essential for oxidative phosphorylation. The complexity of the
mitochondrial translation machinery is remarkable, given that
thepurpose is to synthesizeonly13proteinsof the oxidativephos-
phorylation system. Translation of themtDNA-encodedmRNAs is
dependent on 24mtDNA-encoded genes (2 rRNAs and 22 tRNAs)
and at least 100 nuclear-encoded genes that encode ribosomal
proteins, TFs, tRNA-modifying enzymes, ribosomal biogenesis
factors, tRNA-aminoacyl transferases, and other factors. A large
number of mainly autosomal recessive human diseases are
caused by defective mitochondrial translation, and affected pa-
tients often have neonatal or infantile onset, oftenwith very severe
disease phenotypes. Furthermore, mutations of mtDNA often
impair mitochondrial translation to cause a mosaic pattern of
severe respiratory chain deficiency in disease and aging. Within
the next few years, we can expect a broader and more detailed
molecular knowledge of the mitochondrial translation machinery.
In this regard, an atomic structure of the mammalian mitoribo-
some would provide important mechanistic insights. It stands
clear that a better understandingof the regulation ofmitochondrial
translation should enable the development of specific treatments
aimed at ameliorating the mitochondrial dysfunction found in
mitochondrial disease, age-associated diseases and aging itself.ACKNOWLEDGMENTS
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